Loading
A phase 2 trial of Pembrolizumab, Trifluridine/tipiracil, Regorafenib in colorectal cancer, run by Teclison Ltd., now recruiting.
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC is a phase 2 interventional study registered as NCT04701476 by Teclison Ltd., with 110 participants planned, started 2021-05-20 and due to reach its primary completion in 2027-03-31. Interventions recorded: TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill. Conditions listed: Colorectal Cancer; Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Teclison, Immune checkpoint inhibitors.
Shares Trifluridine/tipiracil, Regorafenib, Colorectal cancer.
Shares Trifluridine/tipiracil, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trifluridine/tipiracil, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trifluridine/tipiracil, Colorectal cancer.
Shares Trifluridine/tipiracil, Regorafenib, Pembrolizumab, Colorectal cancer.
Shares Regorafenib, Immune checkpoint inhibitors.
Shares Regorafenib, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/